SUMITOMO PHARMA CO LTD

Ally Schott's early endometriosis diagnosis at 12 led to limited treatment options and self-taught research. Despite its prevalence affecting 10% of women globally, endometriosis remains underfunded and poorly understood, with only two new drugs approved in the U.S. for pain management in the past decade. Women's health research generally suffers from insufficient funding and information deficits, hindering drug development. Recent federal efforts, including a $100 million investment by the Biden administration, aim to address these gaps, but future priorities under a new administration remain uncertain.

July's Molecules of the Month feature Novartis' molecular glue degrader for sickle cell disease, Pfizer's tinlorafenib for melanoma with brain metastasis, AstraZeneca's AZ-PRMT5i-1 for MTAP-deficient cancers, MTX-531 for dual EGFR/PI3K inhibition, and LifeMine Therapeutics' XC219 discovered via top-down approach. Paxalisib shows promising data in glioblastoma, and Takeda's OX2R-selective agonist offers potential in Alzheimer's disease.